Table 1.
Characteristics of patients on ofatumumab and COVID-19. Levels of CD19, IgG, and IgM levels before the infection are presented as well as PCR findings of nasopharyngeal swabs for the presence of SARS-Cov2 and finding of SARS-Cov2 antibodies after the infection.
| Subject no. | Age, Sex | Ofatumumab exposure (months) | CD19% before | IgM before (g/L) | IgG before (g/L) | Sars-Cov2 PCR | Symptoms onset date | Symptom duration (days) | Date of 1st sample | SARS-CoV2 IgG (U/mL) | Date of 2nd sample | SARS-CoV2 IgG (U/mL) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M, 35 | 15 | 0.0 | 0.59 | 10.60 | + | 22 Sep 2020 | 3 | 14 Jan 2021 | 0.4 | 01 Jun 2021 | <0.4 |
| 2 | F, 31 | 18 | 0.0 | 0.82 | 8.45 | ND | 27 Dec 2020 | 12 | 14 Jan 2021 | <0.4 | 07 Jul 2021 | <0.4 |
| 3 | F, 34 | 18 | 6.4 | 0.38 | 7.95 | + | 10 Dec 2020 | 12 | 03 Feb 2021 | 118 | 01 Jun 2021 | >250 |
| 4 | F, 32 | 18 | 0.0 | 1.91 | 11.0 | + | 12 Nov 2020 | 5 | 01 Feb 2021 | <0.4 | ND | ND |
M-male. F-female. IgM-immunoglobulin M. IgG-immunoglobulin G. PCR-polymerase chain reaction. ND-not done.
Reference range: CD19 (6.5–27.0%), IgM (0.40–2.30 g/L), IgG (5.65–17.65 g/L), ACOV2 S (<0.8 U/mL)